Zhejiang Huahai Pharmaceutical Co., Ltd. – FDA 483, May 31, 2019
This FDA Form 483 was issued to Zhejiang Huahai Pharmaceutical Co. Ltd. in Linhai, China, an API and drug product manufacturer, following an inspection from May 20-31, 2019. The inspection revealed significant deficiencies across multiple quality system areas, including inadequate analytical method validation, a scientifically unsound cleaning validation program, and insufficient evaluation of the solvent recovery process. Additionally, the firm failed to adequately identify unknown peaks, initiate investigations into manufacturing deviations, and implement effective corrective and preventative actions for complaint investigations.
ID · 30c96b5f-fed4-4761-bd29-7764a4ff72bf
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.